TY - JOUR T1 - The role of SGLT-2 inhibitors in managing type 2 diabetes JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 47 LP - 58 DO - 10.3949/ccjm.88a.20088 VL - 88 IS - 1 AU - Yumiko Tsushima AU - M. Cecilia Lansang AU - Vinni Makin Y1 - 2021/01/01 UR - http://www.ccjm.org/content/88/1/47.abstract N2 - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are an exceptionally versatile class of medication, and their glycemic and nonglycemic benefits could help millions of patients with type 2 diabetes. Of note, they have been shown to improve cardiac and renal outcomes, much-needed benefits in patients with type 2 diabetes, who are at a higher risk for developing cardiac and renal dysfunction than those who do not have diabetes. The indications for SGLT-2 inhibitors may continue to expand as ongoing clinical trials provide more insight into these drugs. ER -